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ess: dschui@cuhk.edu.hSummary Study objective: To study the demographics and sputum microbiology of
patients admitted to a teaching hospital with acute exacerbations of chronic
obstructive pulmonary disease (AECOPD).
Design: A retrospective study.
Setting: A tertiary university hospital in Hong Kong.
Patients: All episodes of AECOPD, patient demographics, length of stay, sputum
culture and radiological results admitted in the first half of the year 2000 were
retrieved from hospital records.
Results: There were 329 patients with 418 episodes of AECOPD without
concomitant pneumonia. The age of the patients was 74.478.3 years. The acute
hospital length of stay for an episode of AECOPD was 7.376.5 days. Haemophilus
influenzae was the commonest organism found in sputum (23.1%), followed by
Pseudomonas aeruginosa (6.3%) and Streptococcus pneumoniae (4.0%). Mycobacter-
ium tuberculosis was found in 1.1% of the admissions. Presence of organisms in
sputum had no association with the hospital length of stay and intensive care unit
admissions. In patients whose FEV1 was450% of predicted values, there was a higher
chance of positive sputum growth of H. influenzae than those with FEV1 o50% (16/
44 vs. 31/162 episodes, respectively, P ¼ 0:02).
Conclusions: H. influenzae was the commonest bacterium isolated in sputum in
patients with AECOPD. In areas endemic of tuberculosis, it is advisable to use
fluoroquinolones for AECOPD with caution.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
rbation of COPD; CAP, community acquired pneumonia; CXR, chest radiograph; TB, pulmonary
322195; fax: 852 26489957.
k (D.S.C. Hui).
ARTICLE IN PRESS
Acute exacerbations of COPD 455Introduction
Chronic obstructive pulmonary disease (COPD) is a
common disease worldwide with a significant
morbidity and it incurs heavy utilization of health-
care resources. In Hong Kong, COPD was the fourth
leading cause of death, and accounted for 3% of all
public hospital admissions in 2001. The prevalence
of chronic bronchitis and emphysema was esti-
mated to be 7% and 2%, respectively among those
aged 70 years or over in the general population in
Hong Kong.1 Previous studies have shown that
pulmonary function and quality of life were
adversely affected by frequent exacerbations,
particularly in active smokers.2,3 Infectious agents
are recognized as a major pathogenic factor in
exacerbations. Other contributing factors for ex-
acerbation include air pollution, low temperature
and interruption of regular treatment.4–6
In community-acquired pneumonia (CAP), the
organisms responsible for the infection varied in
different parts of the world. In most countries,
Streptococcal pneumoniae and Haemophilus influ-
enzae were the major organisms responsible for
CAP. Legionella pneumophila, which was estimated
to be the responsible etiological agent for CAP in
2–8% in North America, was an infrequent cause of
pneumonia in Asian countries like Japan.7,8 Current
data on bacteriology related to acute exacerba-
tions of COPD (AECOPD) were mainly derived from
the western countries.9–13 There are very few data
on this aspect within the Asian Pacific region. As our
spectrum of organisms might be different from
those of other countries or regions, it is important
to examine the bacteriology responsible for AE-
COPD, which has important therapeutic implication
for the choice of empirical antibiotic treatment for
this common condition. Thus the aims of this study
were to examine the background, clinical manifes-
tations, and infectious etiologies in the sputum
specimen in relation to clinical outcome in patients
admitted with AECOPD in Hong Kong.Methods
This was a retrospective study based on review of
data from patients who were admitted with
AECOPD to the Prince of Wales Hospital (an acute
hospital in Hong Kong serving a population of
600,000) from January to June 2000. Patients were
identified from the hospital database by Interna-
tional Classification of Diseases 9th Revision Clinical
Modification Codes (ICD-9-CM).14 Patients with the
code numbers 491.21 and 496 were selected (as theprinciple diagnosis or other diagnosis). These codes
included the diagnosis of acute bronchitis with
chronic obstructive pulmonary disease, acute and
chronic obstructive bronchitis, acute exacerbation
of chronic obstructive pulmonary disease and
chronic airway obstruction, not elsewhere classi-
fied.
Hospital records were then retrieved and re-
viewed by the investigators. All patients with
sputum specimen saved for investigations were
included in the study (including routine culture and
mycobacterial culture). When reviewing the case
notes, AECOPD would be considered if the patient
had background COPD with at least two of the
major symptoms (increased dyspnoea, increased
sputum purulence, increased sputum amount) or
one major and one minor symptom (nasal dis-
charge/congestion, wheeze, sore throat,
cough).2,15 Detailed information on the COPD
exacerbations was collected from the case records.
Information collected included the demographic
data, radiological results, sputum culture results,
blood test results, lung function test data, length of
stay in hospital and number of readmissions over 1
year from the first exacerbation in the study
period.
Lung function data of the patients were collected
from their medical records when the patients were
free of acute exacerbations (spirometry at clinic
follow up, either before or after the exacerbation,
within 1 year). All the recorded spirometry tests
were performed in our pulmonary function labora-
tory meeting the standards required by the Amer-
ican Thoracic Society.16 Chest radiograph (CXR)
findings were evaluated by the investigators.
Patients who had new infiltrates on the CXR were
considered to have pneumonia rather than pure
COPD exacerbations and thus would not be included
in the study.
Expectorated sputum was collected into a sterile
container and processed according to standard
procedures.17 Microscopy by Gram staining was
performed for presence of leucocytes, epithelial
cells and organism morphotypes. Specimens with
more than 10 epithelial cells per low power field
were not cultured unless the specimen appeared
purulent or bloodstained. After homogenization
with sputolysin, quantitative culture was per-
formed using a 1 mL standard loop onto blood agar
and chocolate blood agar plates which were
incubated in 5% CO2 at 35 1C for 18–24 h. Culture
plates were reincubated for a further 24 h if there
was no growth after overnight incubation or
predominant morphotype seen in Gram smear had
not yet been isolated. Common lower respiratory
tract pathogens (e.g. S. pneumoniae, H. influen-
ARTICLE IN PRESS
Table 1 Demographic data of patients admitted
with COPD exacerbation (first admission in the
study period) (n ¼ 329).
Age 74.478.3
Sex (M/F) 259/70
Smoking status
Smokers 50 (15.2)
Ex-smokers 270 (82.1)
Non-smokers 8 (2.4)
Social support
Lives with family 257 (78.1)
Home alone 30 (9.1)
Lives in institution 36 (10.9)
Activities of daily living
Can climb at least 12 flight of
stairs
89 (27.1)
Outgoing but level ground
exercise tolerance
149 (45.3)
Homebound 72 (21.9)
Chairbound 11 (3.3)
Use of home O2 76 (23)
Use of non-invasive home
ventilation
4 (0.12)
Lung function (n ¼ 172)
FEV1 percentage predicted 39.59718.95
Medication use
F.W.S. Ko et al.456zae, Morexella catarrhalis) were reported semi-
quantitatively when isolated. Only isolates with
higher than 105 colony forming units were reported
as a positive growth. Potential pathogens (including
Pseudomonas spp. Klebsiella and other Enterobac-
teriaceae spp., Staphylococcus aureus, Candida
spp., Pasteurella spp., b-haemolytic streptococci,
etc.) were reported only when they were present in
heavy or predominant growth, or in the absence of
oral commensals. Acid fast staining and culture for
Mycobacterium species onto Lowenstein–Jensen
medium after decontamination of sputum speci-
mens were performed according to standard
procedures.18
Statistics
Data were analyzed by the Statistical Package of
the Social Science (SPSS) Statistical software for
Window, Version 10.0 (SPSS Inc., IL, USA). The
association between the presence of bacteria in
sputum, the background characteristics and clinical
outcomes of patients (length of hospitalization,
number of readmissions over 1 year period and ICU
admissions) was assessed by Mann–Whitney U test,
chi-square test and Fisher’s exact test as appro-
priate. Data were presented as mean7SD unless
otherwise stated. A P value of less than 0.05 was
considered as significant.Using ICS 66 (20.1)
Using theophyllines 87 (26.4)
Data presented as mean7SD (percentage).Results
A total of 711 episodes of COPD exacerbations (534
patients) were identified from computer records
from January to June 2000. Case records were
retrieved but the records of 18 episodes (10
patients) were missing. In the case records re-
viewed, 574 episodes were related to COPD
exacerbations among 452 patients. Among these,
150 episodes (118 patients) had pneumonic changes
on CXR whereas 418 episodes (329 patients) had no
pneumonic changes on CXR. Six episodes (5
patients) did not have the X-ray changes documen-
ted in case records. Only the 418 episodes without
pneumonic changes on CXR were included in this
study.
Demographic data of the subjects are shown in
Table 1. The average age of the patients was above
70 years with the majority being males (78.7%) and
ex-smokers (82.1%). Among these patients, 53.3%
had lung function tests performed at stable state
within 1 year of the first admission for the AECOPD
in the study period. The mean FEV1 was
39.6719.0% predicted. Only 21.0% of the patientswere on inhaled corticosteroids (ICS) whereas
26.4% were taking oral theophylline before hospi-
talization.
Clinical data of patients admitted to hospital
with AECOPD are shown in Table 2. The average
length of stay in the acute hospital was 7 days.
Fever (437.5 1C) was present in 16.7% of the
episodes. White cell count of X10 109/L was
present in 45.7% of the exacerbations. The number
of re-admissions to hospital within 1 year from the
first admission in the study period was 2.271.8
times. The mortality rate of the patients within one
year was 14.0%.
Among all the episodes of AECOPD, 151(37.8%)
had positive results on routine sputum the three
most common organisms grown in sputum culture
for patients with AECOPD were H. influenzae
(23.1%), P. aeruginosa (6.3%) and S. pneumoniae
(4.0%). The routine sputum culture results are
shown in Fig. 1. Mixed infections were identified in
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Acute exacerbations of COPD 457routine sputum cultures in 53 (13.3%) episodes of
AECOPD.
Readmissions were not caused by the same
previously detected strain of bacteria in the
majority of cases. Only five episodes out of the 70
re-admissions with pure AECOPD (three had H.
influenzae, two had Pseudomonas aeruginosa
whereas 1 had S. pneumonia) had the same
organism grown in sputum in the subsequent
admissions as the first admissions. Mortality had
no correlation with positive sputum cultures, either
as a whole or with each individual organism.
Concerning the resistance pattern of the com-
mon organisms, beta-lactamase activity was found
in 31 out of 92 (33.7%) isolates of H. influenzae. AtTable 2 Clinical data of patients admitted with
acute exacerbation of COPD (by
episodes)(N ¼ 418).
Hospital stay in acute hospital
(days)
7.376.5
Hospital stay in convalescent
hospital (days)
6.879.0
Fever on admission 70 (16.7)
WCC on admission 11.075.2
ICU admission 11 (2.6)
Use of NIPPV 34 (8.1)
Use of mechanical ventilation 8 (1.9)
Data presented as mean7SD (percentage); NIPPV: non-
invasive mechanical ventilation; ICU: intensive care unit;
WCC: total white cell count ( 109/L).
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Figure 1 Bacterial flora in sputum of patieleast intermediate resistance to penicillin was
identified in 4 out of 16 (25%) of S. pneumoniae
isolates.
The mycobacterial culture results are shown in
Fig. 2. A total of nine (2.6%) patients had positive
mycobacterial sputum culture when admitted to
hospital with AECOPD. Among these patients with
positive mycobacterial growth, M. tuberculosis
(MTB) was identified in four (1.1%) patients
whereas atypical mycobacterium was identified in
five (1.4%) of the admissions. The atypical myco-
bacteria included M. chelonae, M. kanassi and M.
fortuitium. Only one patient had positive sputum
growth on both routine culture (Enterobacter) and
mycobacterial culture (M. tuberculosis).
The positive growth of H. influenzae, P. aerugi-
nosa and S. Pneumoniae in the sputum specimen
was found to have no association with the patients’
length of hospitalization, number of re-admissions
over 1 year, number of admissions for COPD over
the past year, ICU admissions, age of patients,
activities of daily living, and co-morbidities such as
congestive heart failure.
Analysis of the relationship between lung func-
tion and presence of bacteria in sputum was
performed in the 206 episodes where lung function
data were available. In patients whose FEV1 was
450% predicted, there was a higher chance of
positive sputum growth of H. influenzae than those
with FEV1o50% (16/44 vs. 31/162 episodes, re-
spectively, P ¼ 0:02). However, no correlation
between other individual organisms or presence
of any organisms with lung function (using anho
m
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Figure 2 Mycobacterial growth from sputum of patients with acute exacerbation of COPD.
F.W.S. Ko et al.458arbitrary FEV1 cut off value of 50% of predicted
values) was observed. If the FEV1 cut off value was
taken as 30% of predicted values (76 episodes had
FEV1o30% and 130 episode had FEV1X30% pre-
dicted normal), no correlation between bacterial
growth and lung function was observed.Discussion
This retrospective study described the demo-
graphics, clinical manifestations and infectious
etiologies in the sputum collected from patients
who had been admitted to hospital with AECOPD in
Hong Kong. We found that 37.8% of our patients
with AECOPD had a positive routine sputum culture.
In addition, M. tuberculosis was detected on
sputum culture in 1.1% of them. In patients whose
FEV1 was 450% of the normal predicted values, a
higher chance of positive growth of H. influenzae
from the sputum was observed.
A prospective study in Netherlands over a 1-year
period found that 50% of patients admitted to
hospital with AECOPD had positive sputum culture.
Pathogens more frequently isolated were H. influ-
enzae (45%), S. pneumoniae (27%), and P. aerugi-
nosa (15%).9 Similarly, two multi-center studies in
Spain found that about half of the patients with
AECOPD requiring hospitalizations had positive
sputum culture.12,13 Similar to other studies,9,12
H. influenzae was the commonest organisms
(23.1%) identified on the sputum culture in our
study. A substantial number of our patients had P.
aeruginosa detected in the sputum though the
percentage (6.3%) was lower than other reports
with a prevalence rate of about 15%.9,12
A previous study found that poor airway function,
defined as FEV1 o50%, was associated with P.
aeruginosa and H. influenzae isolation from spu-
tum.12 Groenewegen and Wouters9 also observedthat the proportion of patients with bacterial
infection was higher in those with FEV1 o50%
predicted. However, they did not identify a positive
relationship between the type of bacteria and lung
function. In contrast, we noted that H. influenzae
was found more commonly in patients whose FEV1
was 450% of predicted normal values than those
with lower level of lung function. This observation
was different from previous studies. The study by
Miravitlles et al.12 involved ambulatory patients in
clinics rather than patients with AECOPD requiring
hospitalizations as in our study. The study of
Groenewegen et al. also involved patients with
AECOPD who required hospitalization. Their pa-
tients also had comparable lung function with our
group of patients. However, the study of Groene-
wegen was of prospective design whereas ours was
a restropective study. As there are only sparse
amount of data in the medical literature on the
relationship between sputum bacteriology and lung
function, more studies are needed to assess the
pattern of bacterial infection in relation to lung
function results.
M. tuberculosis was isolated from sputum in 1.1%
of our patients admitted with AECOPD. A study in
Hong Kong in the 1990s estimated that 12% of
patients admitted to hospital with CAP suffered
from M. tuberculosis infection.19 Hong Kong has
had a high prevalence of pulmonary tuberculosis
(TB). In the year 2003, the TB notification rate was
89.2 per 100,000 population.20 Screening for TB in
patients with AECOPD is essential in this locality
with a high background prevalence of TB infection
as systemic steroid is often prescribed for AECOPD
in order to speed up recovery of airway function
and reduce hospital length of stay.21,22 Early
diagnosis and treatment of TB infection is impor-
tant in preventing spread of the disease in the
community. One should also be cautious about the
use of fluoroquinolones as empirical antibiotic for
treatment of AECOPD or community acquired
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infection as this may result in delay in the diagnosis
and treatment of TB infection.23
Atypical mycobacterium was cultured from the
sputum in 1.4% of our patients with AECOPD. It is
possible that some of our patients might have post-
TB bronchiectasis, which was not easily detected
on plain chest radiographs. Atypical mycobacterial
growth in sputum of these patients might be due to
colonization rather than genuine infection. Never-
theless, careful follow-up with repeated sputum
cultures and chest radiographs and CT scans is
needed in these patients.24
In our study, expectorated sputum was used to
assess infection associated with AECOPD. The
possibility of contamination by saprophytic oro-
pharyngeal flora was a concern. However, with
adherence to strict cytological criteria for report-
ing, it was suggested that culture of expectorated
sputum could reflect the bacterial flora of the
lower airway secretions.25,26 Tools like protected
specimen brush could avoid contamination of
oropharngeal secretions. However, these methods
were invasive and would inflict more discomfort to
patients who already were suffering from AECOPD.
Many studies thus still recommend this easy-to-
obtain and non-invasive method of expectorated
sputum for assessment of the bacteriology in the
airway.12,13,27 In fact, the etiological agents identi-
fied for AECOPD were similar to those studies using
invasive methods like protected specimen brush
and non-invasive methods with expectorated spu-
tum.12,28 It has been noted that bacterial coloniza-
tion may occur in patients with stable COPD. Patel
et al. found that 51.7% of COPD patients at stable
state had possible pathogens colonized in their
lower airway as detected by sputum induction.15
Thus identification of positive sputum culture does
not necessarily indicate an infection. As sputum for
routine bacterial culture was used to assess the
infectious etiology, the role of atypical infectious
agents like Mycoplasma pneumoniae, Chlamydia
pneumoniae and respiratory viruses could not be
assessed. As long as one is aware of the limitations
of expectorated sputum in assessing COPD, its
collection can be useful for analyzing bronchial
infections.
This retrospective study assessed the sputum
bacteriology in patients admitted to hospital with
AECOPD without radiological evidence of pneumo-
nia. While some investigators believe that patients
with concomitant pneumonia and COPD should be
classified as CAP rather than AECOPD, there has
been no universally agreed definition for AECOPD.
AECOPD has been defined as ‘‘sustained worsening
of the patient’s condition from the stable state andbeyond normal day-to-day variations that is acute
in onset and may warrant additional treatment in a
patient with underlying COPD’’.29 According to the
American Thoracic Society guideline30 and the
Global Initiative for Chronic Obstructive Lung
Disease,31 CAP is not excluded from the diagnosis
of AECOPD. Some studies on AECOPD excluded
patients with pneumonia,10,32 whereas others did
not.33,34 Furthermore, for severe CAP patients that
required hospitalization, COPD is the most common
comorbidity.35,36 Nevertheless, we have reported in
this study only patients with non-pneumonic AE-
COPD in order to avoid any ambiguity.
There were several limitations in this study. This
was a retrospective review but the data were well
documented in the majority of cases. Only seven
episodes (six patients) did not have the X-ray
changes documented in the case records. High-
resolution tomography of lungs was not performed
routinely in patients with AECOPD and it was
possible that some patients might have concomi-
tant bronchiectasis, which could predispose to
colonization with pseudomonal and atypical myco-
bacterial species.
In summary, we have shown that Haemophilus
influenzae, Pseudomonas aeruginosa, Streptococ-
cal pneumoniae were the commonest organisms
identified in our patients with AECOPD. It is
essential to screen for sputum AFB and avoid the
use of fluoroquinolone as firstline antibiotic therapy
in COPD patients in areas endemic of TB infection.
Prospective studies are needed to assess the
bacteriology and the treatment outcome for
patients with AECOPD.Acknowledgments
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